Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Statement

29 Jan 2016 07:00

RNS Number : 3769N
Plant Health Care PLC
29 January 2016
 

 

 

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

 

Trading Update

 

Plant Health Care, a leading provider of novel patent-protected biological products to the global agriculture markets, issues the following post year-end trading update ahead of the announcement of the Company's audited full year financial results for the year ended 31st December 2015, which is expected no later than the first week of April. All results provided are preliminary and subject to completion of the 2015 audit.

 

The Company is pleased to report strong financial performance in FY2015 in line with expectations. Progress with our Plant Response Elicitor technology ("PREtec") platform has accelerated.

 

Financial and Commercial Highlights

- Revenue of approximately $7.5m; growth year over year at constant currency was 15%; 9% growth in US$, largely due to the weakness of the Mexican peso

- Sales of the core Harpin products increased by 22%, driven by strong sales in the United States and Europe; Harpin and Myconate® products represented 57% of sales in 2015 (2014: 53%)

- Gross Margin increased to 62% in 2015 from 51% in 2014

- Cash and cash equivalents at 31st December 2015 were $8.4m

- Revenue growth in Mexico of approximately 14% in local currency

- In conjunction with a significant increase in R&D investment to $5.7m in 2015, the overall operating result was a loss of approximately $7.3m in 2015 as compared to $6.1m in 2014

- A roughly two-fold increase in sales to Sym-Agro, a key partner in the Pacific North West

- Achieved the Company's first product registration in Brazil; now preparing for a launch in sugar cane

 

PREtec Highlights

- Signed four evaluation agreements with major players in the agriculture industry for our first family of PREtec peptides, Innatus 3G

- Completed third year of field trials in corn with Innatus 3G, including one peptide variant with three years of field trial data delivering an average yield increase of 9.6 bushels per acre when applied as a seed treatment compared with industry standard treatments alone, with a win rate of 79%, with data from 19 of 20 sites analyzed to date

- Very promising early results on additional peptide families beyond Innatus 3G

- Significantly strengthened the R&D team in Seattle and our licensing capability; moved into expanded laboratories in 3Q

 

Paul Schmidt, CEO, commented:

"2015 was a pivotal year for Plant Health Care. We made substantial progress in growing our commercial business and advancing our PREtec platform.

We are engaging actively with our evaluation partners for Innatus 3G, our first PREtec peptide family, and are encouraged by positive early results. Field and laboratory trials continue and are anticipated to further reinforce the initial promise of this family.

 

Our expanded research team in Seattle is making rapid strides, and we are very encouraged by the early results of studies on other peptide families beyond Innatus 3G. We intend to continue to evaluate and advance these additional peptide families and anticipate presenting at least one new family to potential partners during 2016.

On the commercial side, sales of Harpin αβ continued to grow; we have recorded 22% CAGR from 2012 to 2015, excluding license payments. This is despite strong headwinds in the agriculture industry due to low commodity prices. Increased demand for both Harpin αβ and Myconate in specialty crops has led to strong sales growth in our Mexico subsidiary as well as via Sym-Agro in the Pacific North West. In Brazil, our partner is conducting a further year of trials in sugar cane, prior to its anticipated launch of Harpin αβ.

 

This is an exciting time for Plant Health Care. We are advancing in line with our strategy and confident in our future direction."

 

 

For further information, please contact:

 

Plant Health Care plc

Paul Schmidt, Chief Executive Officer Tel: +1 919 926 1600

Jeffrey Hovey, Chief Financial Officer

 

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke Tel: +44 (0) 20 3100 2000

 

LHA

Ed McGregor / Jody Burfening Tel: +1 (212) 838 3777

 

Company website: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLFFVILSITFIR
Date   Source Headline
29th Nov 201312:12 pmRNSDirector's Shareholding
25th Nov 20133:15 pmRNSDivestment of non-core subsidiary
18th Oct 20135:00 pmRNSTR-1 Notification of Major Interest in Shares
30th Sep 20135:00 pmRNSTotal Voting Rights
23rd Sep 201310:30 amRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSAppointment of Adviser
18th Sep 20133:15 pmRNSDirector/PDMR Shareholding
16th Sep 20137:03 amRNSDirectorate Change
16th Sep 20137:00 amRNSHalf Yearly Report
19th Aug 20132:30 pmRNSBlocklisting Interim Review
30th Jul 20137:01 amRNSUpdate on Harpin
30th Jul 20137:00 amRNSPHC announces plans for Harpin seed treatment
22nd Jul 201311:00 amRNSPHC hires Glen Donald as VP Business Development
19th Jul 20137:00 amRNSHead Office Relocation,Research Facility Expansion
15th Jul 20135:15 pmRNSDirector/PDMR Shareholding
5th Jul 20137:00 amRNSUpdate on CISX Listing
3rd Jul 20137:00 amRNSNew Long-Term Incentive Plan and Grant of Awards
7th Jun 20134:15 pmRNSDirectorate Change
31st May 201311:30 amRNSTotal Voting Rights
21st May 201312:00 pmRNSHarpin Granted Federal Registration in Mexico
10th May 20134:45 pmRNSDirector/PDMR Shareholding
9th May 20131:20 pmRNSDirectorate Change
9th May 20131:20 pmRNSResult of AGM
7th May 201310:00 amRNSDirector/PDMR Shareholding
3rd May 20137:00 amRNSDirector/PDMR Shareholding
1st May 20137:00 amRNSDirector/PDMR Shareholding
1st May 20137:00 amRNSTotal Voting Rights
25th Apr 20137:00 amRNSPHC and Arysta LifeScience sign license agreement
19th Apr 20133:30 pmRNSTR-1 Notification of Major Interest in Shares
18th Apr 20133:33 pmRNSTR-1 Notification of Major Interest in Shares
18th Apr 20133:31 pmRNSTR-1 Notification of Major Interest in Shares
18th Apr 20133:31 pmRNSTR-1 Notification of Major Interest in Shares
16th Apr 20138:23 amRNSRe. Investment
15th Apr 20131:30 pmRNSResult of General Meeting
8th Apr 20135:45 pmRNSPublication of Annual Report and Notice of AGM
2nd Apr 20137:00 amRNSConfirmation of Board Changes
27th Mar 20137:00 amRNSPosting of Circular to Shareholders
26th Mar 20134:19 pmRNSBoard Changes
26th Mar 20134:19 pmRNSPlacing and Subscription
26th Mar 20134:18 pmRNSFinal Results
20th Mar 201311:35 amRNSPHC reaches milestone agreement with Germains
11th Mar 20137:00 amRNSMarket Update
19th Feb 20135:45 pmRNSBlock Listing Six-Monthly Return
24th Jan 20139:30 amRNSHarpin field trials results
18th Jan 20135:00 pmRNSNotification of Major Interest in Shares
10th Jan 201312:45 pmRNSTrading Update
31st Dec 201212:25 pmRNSTotal Voting Rights
30th Nov 201211:45 amRNSTotal Voting Rights
2nd Nov 201212:15 pmRNSNotification of Major Interest in Shares
23rd Oct 20127:00 amRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.